IL135713A0 - Combination of an aldose reductase inhibitor and a glycogen phosphorylase inhibitor - Google Patents

Combination of an aldose reductase inhibitor and a glycogen phosphorylase inhibitor

Info

Publication number
IL135713A0
IL135713A0 IL13571398A IL13571398A IL135713A0 IL 135713 A0 IL135713 A0 IL 135713A0 IL 13571398 A IL13571398 A IL 13571398A IL 13571398 A IL13571398 A IL 13571398A IL 135713 A0 IL135713 A0 IL 135713A0
Authority
IL
Israel
Prior art keywords
inhibitor
combination
aldose reductase
glycogen phosphorylase
reductase inhibitor
Prior art date
Application number
IL13571398A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL135713A0 publication Critical patent/IL135713A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Superheterodyne Receivers (AREA)
  • Noise Elimination (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
IL13571398A 1997-11-21 1998-11-02 Combination of an aldose reductase inhibitor and a glycogen phosphorylase inhibitor IL135713A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6636597P 1997-11-21 1997-11-21
PCT/IB1998/001752 WO1999026659A1 (en) 1997-11-21 1998-11-02 Combination of an aldose reductase inhibitor and a glycogen phosphorylase inhibitor

Publications (1)

Publication Number Publication Date
IL135713A0 true IL135713A0 (en) 2001-05-20

Family

ID=22069038

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13571398A IL135713A0 (en) 1997-11-21 1998-11-02 Combination of an aldose reductase inhibitor and a glycogen phosphorylase inhibitor

Country Status (38)

Country Link
EP (1) EP1032424B9 (zh)
JP (1) JP2002504478A (zh)
KR (2) KR20010032304A (zh)
CN (1) CN1279617A (zh)
AP (1) AP911A (zh)
AR (1) AR016423A1 (zh)
AT (1) ATE205403T1 (zh)
AU (1) AU733304B2 (zh)
BG (1) BG104435A (zh)
BR (1) BR9814698A (zh)
CA (1) CA2310069A1 (zh)
DE (1) DE69801680T2 (zh)
DK (1) DK1032424T3 (zh)
DZ (1) DZ2656A1 (zh)
EA (1) EA002365B1 (zh)
ES (1) ES2161548T3 (zh)
GR (1) GR3037071T3 (zh)
GT (1) GT199800166A (zh)
HR (1) HRP20000327A2 (zh)
HU (1) HUP0100272A3 (zh)
ID (1) ID24524A (zh)
IL (1) IL135713A0 (zh)
IS (1) IS5453A (zh)
MA (1) MA26568A1 (zh)
NO (1) NO20002164L (zh)
OA (1) OA11379A (zh)
PA (1) PA8462301A1 (zh)
PE (1) PE135399A1 (zh)
PL (1) PL340643A1 (zh)
PT (1) PT1032424E (zh)
SK (1) SK7222000A3 (zh)
TN (1) TNSN98211A1 (zh)
TR (1) TR200001451T2 (zh)
UA (1) UA57811C2 (zh)
UY (1) UY25258A1 (zh)
WO (1) WO1999026659A1 (zh)
YU (1) YU30700A (zh)
ZA (1) ZA9810636B (zh)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2535700A (en) * 1999-02-12 2000-08-29 Novo Nordisk A/S Use of pyrrolidine derivatives for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity or appetite regulation
DE122008000018I1 (de) 2000-01-21 2008-08-14 Novartis Pharma Ag Zusammensetzungen bestehend aus Dipeptidylpeptidase-IV Inhibitoren und Antidiabetica
CO5271699A1 (es) * 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
US6570013B2 (en) 2000-02-16 2003-05-27 Pfizer Inc Salts of zopolrestat
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
IL144507A0 (en) * 2000-07-31 2002-05-23 Pfizer Prod Inc Use of glycogen phosphorylase inhibitors to inhibit tumor growth
WO2002098429A1 (en) * 2001-06-07 2002-12-12 Pfizer Products Inc. Ethanolamine, diethanolamine or triethanolamine salt of zopolrestat
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
CA2392486A1 (en) 2002-07-05 2002-12-08 Duchesnay Inc. Pharmaceutical dosage form bearing pregnancy-friendly indicia
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
US7317109B2 (en) 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7576121B2 (en) 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7767828B2 (en) 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
CA2545311C (en) 2003-11-12 2012-01-03 Phenomix Corporation Heterocyclic boronic acid compounds
JP2008505975A (ja) 2004-07-12 2008-02-28 フェノミックス コーポレーション 制約されたシアノ化合物
US7226942B2 (en) 2004-11-15 2007-06-05 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006053274A2 (en) 2004-11-15 2006-05-18 Bristol-Myers Squibb Company 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7365061B2 (en) 2004-11-15 2008-04-29 Bristol-Myers Squibb Company 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7223786B2 (en) 2004-11-15 2007-05-29 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
US20060235028A1 (en) 2005-04-14 2006-10-19 Li James J Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
CA2622608C (en) 2005-09-14 2014-08-19 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
EP2046753A2 (en) 2006-07-06 2009-04-15 Brystol-Myers Squibb Company Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
WO2008130951A1 (en) 2007-04-17 2008-10-30 Bristol-Myers Squibb Company Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type i inhibitors
EP2144902B1 (en) 2007-05-04 2012-05-16 Bristol-Myers Squibb Company [6,6]and [6,7]-bicyclic gpr119 g protein-coupled receptor agonists
JP2010526146A (ja) 2007-05-04 2010-07-29 ブリストル−マイヤーズ スクイブ カンパニー [6,5]−二環式gpr119gタンパク質結合受容体アゴニスト
EP2170864B1 (en) 2007-07-17 2011-09-14 Bristol-Myers Squibb Company Pyridone gpr119 g protein-coupled receptor agonists
TW201006821A (en) 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
CN102834393B (zh) 2010-02-03 2015-07-22 武田药品工业株式会社 细胞凋亡信号调节激酶1抑制剂
US8415367B2 (en) 2010-04-08 2013-04-09 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridinone analogues as GPR119 modulators
JP2013523894A (ja) 2010-04-14 2013-06-17 ブリストル−マイヤーズ スクイブ カンパニー 新規グルコキナーゼアクチベーターおよびその使用方法
EP2566862B1 (en) 2010-05-06 2015-09-16 Bristol-Myers Squibb Company Benzofuranyl analogues as gpr119 modulators
BR112012028445A2 (pt) 2010-05-06 2016-07-19 Bristol Myers Squibb Co compostos de heteroarila bicíclica como moduladores de gpr119
PL2665477T3 (pl) 2011-01-20 2016-05-31 Bionevia Pharmaceuticals Inc Kompozycje epalrestatu lub jego pochodnej o zmodyfikowanym uwalnianiu i sposoby ich stosowania
WO2013173198A1 (en) 2012-05-16 2013-11-21 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridone analogues as gpr119 modulators
US9580422B2 (en) 2013-10-22 2017-02-28 Bristol-Myers Squibb Company Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
WO2018017910A1 (en) 2016-07-22 2018-01-25 Bristol-Myers Squibb Company Glucokinase activators and methods of using same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4825448A (en) * 1986-08-07 1989-04-25 International Mobile Machines Corporation Subscriber unit for wireless digital telephone system
DE3889326D1 (de) * 1988-05-27 1994-06-01 Itt Ind Gmbh Deutsche Korrekturschaltung für ein digitales Quadratur-Signalpaar.
US5391551A (en) * 1993-05-10 1995-02-21 Pfizer Inc. Method of lowering blood lipid levels
DK0832066T3 (da) * 1995-06-06 2001-11-19 Pfizer Substituerede N-(indol-2-carbonyl)amider og derivater som glycogenphosphorylaseinhibitorer
ATE206702T1 (de) * 1995-06-06 2001-10-15 Pfizer Substituierte n-(indol-2-carbonyl)-glycinamide und derivate als glycogen phosphorylase inhibitoren

Also Published As

Publication number Publication date
MA26568A1 (fr) 2004-12-20
PE135399A1 (es) 2000-01-15
AU9555898A (en) 1999-06-15
UA57811C2 (uk) 2003-07-15
CN1279617A (zh) 2001-01-10
PA8462301A1 (es) 2000-05-24
TR200001451T2 (tr) 2002-06-21
BR9814698A (pt) 2000-10-03
JP2002504478A (ja) 2002-02-12
NO20002164L (no) 2000-07-19
EP1032424A1 (en) 2000-09-06
KR100661214B1 (ko) 2006-12-26
DE69801680T2 (de) 2002-02-07
AU733304B2 (en) 2001-05-10
IS5453A (is) 2000-04-14
CA2310069A1 (en) 1999-06-03
AP9801401A0 (en) 1998-12-31
GT199800166A (es) 2000-04-19
HRP20000327A2 (en) 2001-02-28
WO1999026659A1 (en) 1999-06-03
UY25258A1 (es) 2000-12-29
AP911A (en) 2000-12-07
PL340643A1 (en) 2001-02-12
ID24524A (id) 2000-07-20
GR3037071T3 (en) 2002-01-31
OA11379A (en) 2004-01-28
PT1032424E (pt) 2001-12-28
HUP0100272A3 (en) 2002-11-28
EP1032424B9 (en) 2004-10-06
NO20002164D0 (no) 2000-04-27
DZ2656A1 (fr) 2003-03-22
ES2161548T3 (es) 2001-12-01
TNSN98211A1 (fr) 2005-03-15
EA200000433A1 (ru) 2000-12-25
YU30700A (sh) 2002-12-10
ZA9810636B (en) 2000-05-22
AR016423A1 (es) 2001-07-04
EP1032424B1 (en) 2001-09-12
EA002365B1 (ru) 2002-04-25
KR20010032304A (ko) 2001-04-16
BG104435A (bg) 2001-01-31
ATE205403T1 (de) 2001-09-15
DE69801680D1 (de) 2001-10-18
DK1032424T3 (da) 2001-11-19
SK7222000A3 (en) 2001-09-11
HUP0100272A2 (hu) 2001-06-28
KR20010032300A (ko) 2001-04-16

Similar Documents

Publication Publication Date Title
GR3037071T3 (en) Combination of an aldose reductase inhibitor and a glycogen phosphorylase inhibitor
EP1009415A4 (en) INHIBITORS OF $ g (b) -LACTAMASES AND THEIR USES
GB2338735B (en) Bottomhole assembly and methods of use
AU713068C (en) Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives
PL335166A1 (en) Synergic combination of sulphonylurea and glytazone
HK1022105A1 (en) Naringin and naringenin as 3-hydroxy-3-methylglutaryl coa(hmg-coa) reductase inhibitor
EP0999876A4 (en) STEREOTAXIC RADIOTHERAPY AND PREVENTION OF RESTENOSIS
AU9781998A (en) Huchordin and uses thereof
PL341335A1 (en) Combination of ace and mmp inhibitors
GB9827391D0 (en) Aldose reductase inhibitors and pharmaceutical compositions
PL341709A1 (en) Structural combination of rubber and metal
EP1379633A4 (en) ENZYMATIC CHANGE OF SEEDS VAN PLANTAGO PSYLLIUM
HUP9800146A3 (en) Thalidomide-derivatives and use of them
AU8108998A (en) Aprotinin variants with improved properties and bikunins of aprotinin variants
AU5186898A (en) Electronic key and electronic lock
AU2580299A (en) Synthesis of dysidiolide and uses thereof
EP0892354B8 (en) Efficient representation and transmission of objects with variants
AU9271998A (en) Buoyant and/or thermally insulating articles
GB2331343B (en) Fixings and methods of assembly
ZA987425B (en) Phenylethanolaminotetralin derivatives and bronchodilators
PL338862A1 (en) Derivatives of 2-oxypyroimidin-4-one and 2-oxypyroimidin-4-thione
TW365309U (en) Composite door of wood and metal
TW383110U (en) Combination structure of wrist rest and keyboard
AU5927298A (en) Shipping assembly and method of use
TW301360U (en) Combination structure of aluminum door and flame